Imperial College London
Alternate

ProfessorWaljitDhillo

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Endocrinology & Metabolism
 
 
 
//

Contact

 

+44 (0)20 7594 3487w.dhillo Website

 
 
//

Assistant

 

Ms Suzanne Wheeler +44 (0)20 7594 3487

 
//

Location

 

6N6ECommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Abbara:2022:clinem/dgab617,
author = {Abbara, A and Al-Memar, M and Phylactou, M and Daniels, E and Patel, B and Eng, PC and Nadir, R and Izzi-Engbeaya, C and Clarke, SA and Mills, EG and Hunjan, T and Pacuszka, E and Yang, L and Bech, P and Tan, T and Comninos, AN and Kelsey, TW and Kyriacou, C and Fourie, H and Bourne, T and Dhillo, WS},
doi = {clinem/dgab617},
journal = {J Clin Endocrinol Metab},
pages = {e71--e83},
title = {Changes in Circulating Kisspeptin Levels During Each Trimester in Women With Antenatal Complications.},
url = {http://dx.doi.org/10.1210/clinem/dgab617},
volume = {107},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - CONTEXT: Antenatal complications such as hypertensive disorders of pregnancy (HDP), fetal growth restriction (FGR), gestational diabetes (GDM), and preterm birth (PTB) are associated with placental dysfunction. Kisspeptin has emerged as a putative marker of placental function, but limited data exist describing circulating kisspeptin levels across all 3 trimesters in women with antenatal complications. OBJECTIVE: We aimed to assess whether kisspeptin levels are altered in women with antenatal complications. METHODS: Women with antenatal complications (n=105) and those with uncomplicated pregnancies (n=265) underwent serial ultrasound scans and blood sampling at the Early Pregnancy Assessment Unit at Hammersmith Hospital, UK, at least once during each trimester (March 2014 to March 2017). The women with antenatal complications (HDP [n=32], FGR [n=17], GDM [n=35], PTB [n=11], and multiple complications [n=10]) provided 373 blood samples and the controls provided 930 samples. Differences in circulating kisspeptin levels were assessed. RESULTS: Third-trimester kisspeptin levels were higher than controls in HDP but lower in FGR. The odds of HDP adjusted for gestational age, maternal age, ethnicity, BMI, smoking, and parity were increased by 30% (95% CI, 16%-47%; P<0.0001), and of FGR were reduced by 28% (95% CI, 4-46%; P=0.025), for every 1 nmol/L increase in plasma kisspeptin. Multiple of gestation-specific median values of kisspeptin were higher in pregnancies affected by PTB (P=0.014) and lower in those with GDM (P=0.020), but not significantly on multivariable analysis. CONCLUSION: We delineate changes in circulating kisspeptin levels at different trimesters and evaluate the potential of kisspeptin as a biomarker for antenatal complications.
AU  - Abbara,A
AU  - Al-Memar,M
AU  - Phylactou,M
AU  - Daniels,E
AU  - Patel,B
AU  - Eng,PC
AU  - Nadir,R
AU  - Izzi-Engbeaya,C
AU  - Clarke,SA
AU  - Mills,EG
AU  - Hunjan,T
AU  - Pacuszka,E
AU  - Yang,L
AU  - Bech,P
AU  - Tan,T
AU  - Comninos,AN
AU  - Kelsey,TW
AU  - Kyriacou,C
AU  - Fourie,H
AU  - Bourne,T
AU  - Dhillo,WS
DO  - clinem/dgab617
EP  - 83
PY  - 2022///
SP  - 71
TI  - Changes in Circulating Kisspeptin Levels During Each Trimester in Women With Antenatal Complications.
T2  - J Clin Endocrinol Metab
UR  - http://dx.doi.org/10.1210/clinem/dgab617
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34427658
UR  - http://hdl.handle.net/10044/1/91278
VL  - 107
ER  -
Download